Literature DB >> 9509073

Subclinical Cushing's syndrome in adrenal incidentaloma.

M Terzolo1, G Osella, A Alì, G Borretta, F Cesario, P Paccotti, A Angeli.   

Abstract

OBJECTIVE: Some patients with incidentally discovered adrenal adenomas display autonomous cortisol secretion not fully restrained by pituitary feedback, a condition that may be defined as subclinical Cushing's syndrome. We have evaluated the presence of subclinical Cushing's syndrome and its natural history in a cohort of patients with incidentally discovered adrenal adenomas. PATIENTS: Fifty-three consecutive patients (30 women and 23 men; median age 58 years, range 18-81 years) were studied. Diagnostic procedures were initiated for extra-adrenal complaints. Patients with known extra-adrenal malignancies or patients with hypertension of possible endocrine origin were excluded. MEASUREMENTS: All patients underwent the following endocrine evaluation: (1) measurement of DHEA-S at 0800 h, (2) measurement of serum cortisol at 0800 and 2400 h, (3) measurement of the 24-h excretion of urinary free cortisol (UFC), (4) overnight low-dose dexamethasone suppression test, (5) measurement of plasma ACTH at 0800 h (mean of at least two samples on different days), (6) oCRH stimulation test. Different groups of healthy subjects recruited from the hospital medical staff and their relatives served as controls for the various tests. The same endocrine work-up was repeated after 12 months in 25 patients. All patients were followed up at regular intervals for at least 12 months with clinical examination and abdominal computed tomography. Subclinical hypercortisolism was arbitrarily defined as definitive, probable or possible, according to the degree of endocrine abnormalities.
RESULTS: UFC was significantly higher in patients with incidentaloma than in controls (262, 25-690 nmol/24 h versus 165, 25-772 nmol/24 h; P = 0.012). The percentage of subjects who did not suppress on dexamethasone was greater among patients than among healthy subjects (9/53 (17%) versus 5/103 (5%), P = 0.026). Plasma ACTH concentrations were lower in patients with adrenal incidentaloma than in controls (3, 1-9 pmol/l versus 5, 1-14 pmol/l; P = 0.014). These findings consistently point toward a functional autonomy of the adrenal adenomas even if the degree of cortisol excess is mild. Three patients fulfilled the criteria for definitive subclinical hypercortisolism, five for probable and two possible, but none of them experienced clinical and/or biochemical progression to overt hypercortisolism after 12 months. During follow-up, no signs of extra-adrenal malignancy became manifest and the size of the mass did not increase significantly in any patient.
CONCLUSIONS: This study provides a clear demonstration of the current opinion that some patients with incidentally discovered adrenal adenomas may be exposed to a subtle, silent hypercortisolism. In some patients, in whom the clustering of more abnormalities in the hypothalamo-pituitary-adrenal axis occurs, subclinical Cushing's syndrome could be assumed. This term should be preferred to that of pre-clinical Cushing's syndrome since the biochemical abnormalities do not become clinically manifest, at least in the short term.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9509073     DOI: 10.1046/j.1365-2265.1998.00357.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  32 in total

1.  Pheochromocytoma combined with pre-clinical Cushing's syndrome in the same adrenal gland.

Authors:  C Erem; A Hacihasanoglu; H O Ersöz; A K Reis; A Calik; K Ukinç; M Koçak
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

Review 2.  Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications.

Authors:  S Tsagarakis; D Vassiliadi; N Thalassinos
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.

Authors:  E Grossrubatscher; F Vignati; M Possa; P Lohi
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

4.  Increased ratio of mRNA expression of the genes CYP17 and CYP11B1 indicates autonomous cortisol production in adrenocortical tumors.

Authors:  U Enberg; J Hennings; C Volpe; P Hellman; A Höög; B Hamberger; M Thorén
Journal:  J Endocrinol Invest       Date:  2009-06-24       Impact factor: 4.256

5.  Echocardiographic alterations in patients with non-functioning adrenal incidentaloma.

Authors:  F Ermetici; C Dall'Asta; A E Malavazos; C Coman; L Morricone; V Montericcio; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Guidelines for the management of the incidentally discovered adrenal mass.

Authors:  Anil Kapoor; Topher Morris; Ryan Rebello
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

7.  Primary aldosteronism associated with subclinical Cushing syndrome.

Authors:  K Fujimoto; S Honjo; H Tatsuoka; Y Hamamoto; Y Kawasaki; A Matsuoka; H Ikeda; Y Wada; H Sasano; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

8.  Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma.

Authors:  Gianluca Iacobellis; Luigi Petramala; Giuseppe Barbaro; Atil Y Kargi; Valentina Serra; Laura Zinnamosca; Luciano Colangelo; Cristiano Marinelli; Antonio Ciardi; Giorgio De Toma; Claudio Letizia
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

9.  GH secretion reserve in subclinical hypercortisolism.

Authors:  Serena Palmieri; Valentina Morelli; Antonio Stefano Salcuni; Cristina Eller-Vainicher; Elisa Cairoli; Volha V Zhukouskaya; Paolo Beck-Peccoz; Alfredo Scillitani; Iacopo Chiodini
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

Review 10.  Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis.

Authors:  Stavroula A Paschou; Eleni Kandaraki; Fotini Dimitropoulou; Dimitrios G Goulis; Andromachi Vryonidou
Journal:  Endocrine       Date:  2015-10-24       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.